The Genomics Facility combines the expertise and instrumentation of two previous shared resource laboratories, the Microarray Facility and the Molecular Diagnosis and Genotyping Facility, to provide an integrated set of services for DNA and RNA profiling. These services are delivered by experienced genomics professionals, including a newly strengthened and focused bioinformatics support staff. Abramson Cancer Center (ACC) members benefit from consultations and training available throughout their projects, including during experimental design and budget development, sample accrual. Facility quality control assays and lab work, data management and analyses, and manuscript preparation. The Facility supports quantitative RNA profiling by Affymetrix GeneChips, lllumina BeadChips, real-time PCR, Sequenom custom multiplex assays, and High-Throughput Genomics custom profiling. DNA profiling of custom panels of sequence polymorphisms are conducted by quantitative PCR, Sequenom assays, and lllumina GoldenGate genotyping, while whole-genome assays are available on Affymetrix SNP GeneChip and lllumina Infinium platforms. Several other services including microRNA profiling, epigenetic DNA assays, and translational molecular diagnostics for clinical research are offered using these platforms. Massively parallel sequencing on an lllumina Solexa Genome Analyzer expands existing assays with genomic coverage and resolution not previously possible, and creates opportunities for new genomics applications in cancer biology. The integration of all these services facilitates gene discovery, functional characterization, and other basic research efforts to elucidate the molecular pathogenesis of human cancers. In addition, molecular profiling at the DNA and RNA levels can be used to assist Abramson Cancer Center investigators in cancer diagnosis, subclassification, risk prediction and selection of appropriate therapy. Over 70 ACC members used the facility in the last year. ACC member usage was 34% of the total core usage. CCSG support represents 8% of the proposed core budget with the remaining funding from charge backs, grants/contracts, and institutional support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016520-37
Application #
8567195
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
37
Fiscal Year
2013
Total Cost
$299,310
Indirect Cost
$90,212
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Dannoon, Shorouk; Ganguly, Tanushree; Cahaya, Hendry et al. (2016) Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer. J Med Chem 59:5684-94
Kumar, Anita J; Gimotty, Phyllis A; Gelfand, Joel et al. (2016) Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. Am J Hematol 91:1107-1112
Karunamuni, Roshan; Naha, Pratap C; Lau, Kristen C et al. (2016) Development of silica-encapsulated silver nanoparticles as contrast agents intended for dual-energy mammography. Eur Radiol 26:3301-9
Vachani, Anil; Wong, Yu-Ning; Israelite, Jennifer et al. (2016) Validation of Molecular Pathology Codes for the Identification of Mutational Testing in Lung and Colon Cancer. Med Care :
Ruella, Marco; Barrett, David M; Kenderian, Saad S et al. (2016) Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest 126:3814-3826
Heneghan, Mallorie B; Rheingold, Susan R; Li, Yimei et al. (2016) Treatment of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 16:223-229.e2
Clark, A S; DeMichele, A; Mankoff, D (2016) HER2 imaging in the ZEPHIR study. Ann Oncol 27:555-7
Bartlett, Edmund K; Peters, Madalyn G; Blair, Anne et al. (2016) Identification of Patients with Intermediate Thickness Melanoma at Low Risk for Sentinel Lymph Node Positivity. Ann Surg Oncol 23:250-6
Walsh, Michael F; Nathanson, Katherine L; Couch, Fergus J et al. (2016) Genomic Biomarkers for Breast Cancer Risk. Adv Exp Med Biol 882:1-32
Zhang, Zi; Brown, Justin C; O'Malley Jr, Bert W et al. (2016) Post-treatment weight change in oral cavity and oropharyngeal squamous cell carcinoma. Support Care Cancer 24:2333-40

Showing the most recent 10 out of 848 publications